Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
复制标题
DOI：
10.4161/cbt.8.13.8726
复制
发表时间：
2009-07
影响因子：
3.6
通讯作者：
Bhalla KN
中科院分区：
文献类型：
--
作者：
Rao R;Lee P;Fiskus W;Yang Y;Joshi R;Wang Y;Buckley K;Balusu R;Chen J;Koul S;Joshi A;Upadhyay S;Tao J;Sotomayor E;Bhalla KN
Heat shock protein (hsp) 90 inhibitors promote proteasomal degradation of pro-growth and pro-survival hsp90 client proteins, including CDK4, c-RAF and AKT, and induce apoptosis of human lymphoma cells. The pan-histone deacetylase inhibitor vorinostat has also been shown to induce growth arrest and apoptosis of lymphoma cells. Here, we determined the effects of the more soluble, orally bio-available, geldanamycin analogue 17-NN-dimethyl ethylenediamine geldanamycin (DMAG, Kosan Biosciences Inc) and/or vorinostat in cultured and primary human MCL cells. While vorinostat induced accumulation in the G1 phase, treatment with DMAG arrested MCL cells in the G2/M phase of the cell cycle. Both agents dose-dependently induced apoptosis of MCL cells. Vorinostat also induced hyperacetylation of hsp90 and disrupted the association of hsp90 with its co-chaperones p23 and cdc37, as well as with its client proteins CDK4 and c-RAF. Treatment of MCL cells with vorinostat or 17-DMAG was associated with the induction of p21 and p27, as well as with depletion of c-Myc, c-RAF, AKT and CDK4. Compared to treatment with either agent alone, co-treatment with DMAG and vorinostat markedly attenuated the levels of cyclin D1 and CDK4, as well as of c-Myc, c-RAF and AKT. Combined treatment with DMAG and vorinostat synergistically induced apoptosis of the cultured MCL cells, as well as induced more apoptosis of primary MCL cells than either agent alone. Therefore, these findings support the rationale to determine the in vivo efficacy of co-treatment with vorinostat and DMAG against human MCL cells.
登录
查看更多内容
影响因子：
11.5
作者：
Alao, JP;Lam, EWF;Vigushin, DM
通讯作者：
Vigushin, DM
影响因子：
11.4
作者：
BODRUG, SE;WARNER, BJ;ADAMS, JM
通讯作者：
ADAMS, JM
影响因子：
3.4
作者：
Caraway, NP;Gu, J;Katz, R
通讯作者：
Katz, R
影响因子：
4.8
作者：
Bali, P;Pranpat, M;Bhalla, K
通讯作者：
Bhalla, K
影响因子：
20.3
作者：
George, P;Bali, P;Bhalla, K
通讯作者：
Bhalla, K